- The recent release of phase 2a data on Tezspire, the asthma biologic developed by AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN), brings a ray of hope for patients battling chronic obstructive pulmonary disease (COPD).
- Results from the COURSE trial, while not statistically significant, suggest that patients treated with Tezspire experienced a 17% decrease in the annual rate of moderate or severe COPD exacerbations when compared to those on a placebo over a year.
- Furthermore, for patients with blood eosinophil counts equal to or greater than 150 cells/µL, tezepelumab led to a “nominally significant” 37% reduction in the rate of exacerbations compared to the placebo.
Additional Insights on Tezspire’s Potential